These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15584437)

  • 1. [New effect biomarkers].
    De Palma G; Corradi M; Mutti A; Baccarelli A; Pesatori A; Bertazzi PA
    G Ital Med Lav Ergon; 2004; 26(4):302-10. PubMed ID: 15584437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New biomarkers of exposure].
    Apostoli P; Bergonzi R; Catalani S; Neri G; Sarnico M; Foà V; Fustinoni S; Colombi A; Buratti M; Campo L; Scibetta L; Sannolo N; Pieri M; Basile A; Bartolucci GB; Carrieri M; Scapellato ML; Manini P; Poli D; Corradi M; Andreoli R; Goldoni M; Mutti A; Imbriani M; Ghittori S; Maestri L; Negri S; Pira E; Pavan I; Discalzi G; Perbellini L
    G Ital Med Lav Ergon; 2004; 26(4):278-97. PubMed ID: 15584435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of biomarkers in monitoring exposures to chemicals: present position, future prospects.
    Watson WP; Mutti A
    Biomarkers; 2004; 9(3):211-42. PubMed ID: 15764289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toxicological significance of biological markers].
    Manno M; Sannolo N
    G Ital Med Lav Ergon; 2004; 26(4):270-7. PubMed ID: 15584434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity.
    Merrick BA; Bruno ME
    Curr Opin Mol Ther; 2004 Dec; 6(6):600-7. PubMed ID: 15663324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of human populations for early markers of cadmium toxicity: a review.
    Fowler BA
    Toxicol Appl Pharmacol; 2009 Aug; 238(3):294-300. PubMed ID: 19433102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine.
    Collins CD; Purohit S; Podolsky RH; Zhao HS; Schatz D; Eckenrode SE; Yang P; Hopkins D; Muir A; Hoffman M; McIndoe RA; Rewers M; She JX
    Vascul Pharmacol; 2006 Nov; 45(5):258-67. PubMed ID: 17030152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in environmental carcinogenesis research: striving for a new momentum.
    Kyrtopoulos SA
    Toxicol Lett; 2006 Mar; 162(1):3-15. PubMed ID: 16321483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toxicogenomics. New perspectives for the molecular toxicology].
    Lutz W; Kur B
    Med Pr; 2004; 55(2):193-202. PubMed ID: 15524089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biomarkers for aflatoxins and their application to human cancer prevention.
    Groopman JD; Wogan GN; Roebuck BD; Kensler TW
    Cancer Res; 1994 Apr; 54(7 Suppl):1907s-1911s. PubMed ID: 8137310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prioritizing future resources for epidemiologic research on old and newly emerging occupational hazards.
    Checkoway H
    Med Lav; 2006; 97(2):175-81. PubMed ID: 17017344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Individual susceptibility to occupational carcinogens: the evidence from biomonitoring and molecular epidemiology studies].
    Pavanello S; Clonfero E
    G Ital Med Lav Ergon; 2004; 26(4):311-21. PubMed ID: 15584438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biologically effective dose biomarkers].
    Miraglia N; Assennato G; Clonfero E; Fustinoni S; Sannolo N
    G Ital Med Lav Ergon; 2004; 26(4):298-301. PubMed ID: 15584436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database.
    Kondo C; Minowa Y; Uehara T; Okuno Y; Nakatsu N; Ono A; Maruyama T; Kato I; Yamate J; Yamada H; Ohno Y; Urushidani T
    Toxicology; 2009 Nov; 265(1-2):15-26. PubMed ID: 19761811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of genomics and proteomics in nephrology.
    Stojnev S; Pejcic M; Dolicanin Z; Velickovic LJ; Dimov I; Stefanovic V
    Ren Fail; 2009; 31(8):765-72. PubMed ID: 19814648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics and proteomics: emerging technologies in clinical cancer research.
    Chung CH; Levy S; Chaurand P; Carbone DP
    Crit Rev Oncol Hematol; 2007 Jan; 61(1):1-25. PubMed ID: 17015021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.